|
Gene: CNKSR2 |
Gene summary for CNKSR2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CNKSR2 | Gene ID | 22866 |
Gene name | connector enhancer of kinase suppressor of Ras 2 | |
Gene Alias | CNK2 | |
Cytomap | Xp22.12 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8WXI2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22866 | CNKSR2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.36e-04 | 1.89e-01 | -0.1808 |
22866 | CNKSR2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.89e-09 | 4.13e-01 | -0.0811 |
22866 | CNKSR2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.54e-03 | 2.54e-01 | -0.1088 |
22866 | CNKSR2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.39e-09 | 2.57e-01 | -0.1954 |
22866 | CNKSR2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.54e-05 | 1.93e-01 | -0.1464 |
22866 | CNKSR2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.04e-02 | 1.86e-01 | -0.059 |
22866 | CNKSR2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.26e-03 | 3.13e-01 | -0.0179 |
22866 | CNKSR2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 9.71e-08 | 4.64e-01 | 0.0112 |
22866 | CNKSR2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.83e-31 | 6.33e-01 | 0.294 |
22866 | CNKSR2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.63e-07 | 2.90e-01 | 0.281 |
22866 | CNKSR2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.55e-05 | 1.25e-01 | 0.3005 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0099173 | Colorectum | AD | postsynapse organization | 51/3918 | 168/18723 | 2.47e-03 | 1.90e-02 | 51 |
GO:0050808 | Colorectum | AD | synapse organization | 112/3918 | 426/18723 | 4.25e-03 | 2.92e-02 | 112 |
GO:00991731 | Colorectum | SER | postsynapse organization | 46/2897 | 168/18723 | 5.20e-05 | 1.25e-03 | 46 |
GO:00508081 | Colorectum | SER | synapse organization | 85/2897 | 426/18723 | 7.17e-03 | 4.99e-02 | 85 |
GO:00991732 | Colorectum | MSS | postsynapse organization | 48/3467 | 168/18723 | 9.32e-04 | 9.44e-03 | 48 |
GO:00508082 | Colorectum | MSS | synapse organization | 101/3467 | 426/18723 | 3.96e-03 | 2.89e-02 | 101 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CNKSR2 | SNV | Missense_Mutation | c.479T>C | p.Val160Ala | p.V160A | Q8WXI2 | protein_coding | deleterious(0) | benign(0.358) | TCGA-B5-A11X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | |
CNKSR2 | SNV | Missense_Mutation | novel | c.1388N>T | p.Arg463Ile | p.R463I | Q8WXI2 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.1047N>T | p.Gln349His | p.Q349H | Q8WXI2 | protein_coding | tolerated(0.56) | benign(0.033) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.470G>A | p.Arg157Lys | p.R157K | Q8WXI2 | protein_coding | tolerated(1) | benign(0.04) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.754C>T | p.Arg252Trp | p.R252W | Q8WXI2 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.1524C>A | p.His508Gln | p.H508Q | Q8WXI2 | protein_coding | tolerated(0.1) | benign(0.245) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.2222C>A | p.Ser741Tyr | p.S741Y | Q8WXI2 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.3013N>G | p.Thr1005Ala | p.T1005A | Q8WXI2 | protein_coding | tolerated(1) | benign(0) | TCGA-BG-A220-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.2695N>A | p.Glu899Lys | p.E899K | Q8WXI2 | protein_coding | tolerated(0.28) | benign(0.005) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNKSR2 | SNV | Missense_Mutation | novel | c.434N>T | p.Ser145Leu | p.S145L | Q8WXI2 | protein_coding | tolerated(0.09) | benign(0.161) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |